Norifaz

Active Ingredient:: Risedronate Sodium
Origin:: EU

Norifaz (Risedronate Sodium)

Q: What is Norifaz used for?

Norifaz contains risedronate sodium and is prescribed for the treatment of osteoporosis in postmenopausal women and men, as well as for Paget's disease of bone. In each condition the drug works to reduce excessive bone resorption, helping to increase bone density and lower the risk of fractures.

Q: How does Risedronate Sodium work?

Risedronate sodium binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and blocks the mevalonate pathway, preventing prenylation of essential signaling proteins. This inhibition reduces osteoclast maturation and activity, leading to decreased bone breakdown and a net gain in bone mineral density.

Q: What is the usual dose of Norifaz?

The dosage of Norifaz is determined by the prescribing clinician based on the patient’s specific condition, renal function, and other clinical factors. Healthcare professionals follow approved prescribing information and adjust the regimen as needed; patients should follow the prescriber’s instructions and not alter the dose on their own.

Q: Is Norifaz safe during pregnancy or breastfeeding?

Safety data for risedronate sodium in pregnancy and lactation are limited, and the drug is generally not recommended for use in these populations. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

Q: How do I order Norifaz from GNH India?

To request Norifaz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Q: How does Norifaz compare with other osteoporosis drugs?

Norifaz (risedronate) belongs to the bisphosphonate class, similar to alendronate and ibandronate. Compared with some alternatives, risedronate offers a weekly oral dosing schedule and a well‑characterized safety profile. Choice of therapy depends on patient preference, renal function, risk of gastrointestinal side effects, and physician assessment.

Q: What are the storage and handling requirements for Norifaz?

Norifaz should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in a bathroom or near a kitchen sink where humidity is high.

Q: How is Norifaz administered?

Norifaz is taken orally with a full glass of plain water, preferably on an empty stomach. Patients should remain upright for at least 30 minutes after dosing and avoid eating, drinking, or taking other medications during that time to minimize esophageal irritation and ensure optimal absorption.

Q: What are the most serious risks associated with Norifaz?

The most serious adverse events linked to risedronate include osteonecrosis of the jaw, atypical femur fractures, severe esophageal ulceration, acute hypocalcemia, and rare severe allergic reactions. Patients should report persistent jaw pain, unusual thigh pain, difficulty swallowing, or signs of an allergic response to their clinician promptly.

Q: Who should not use Norifaz?

Norifaz is contraindicated in individuals with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to risedronate or other bisphosphonates, and those with active esophageal disorders that delay emptying. It should also be avoided in patients unable to sit or stand upright for at least 30 minutes after dosing.

Risedronate Sodium, the active ingredient in Norifaz, is a bisphosphonate presented as an oral formulation for oral use. It is indicated for the treatment of osteoporosis in postmenopausal women and men, as well as for Paget's disease of bone.

GNH India supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to global quality standards and provides reliable sourcing for regulated markets through established distribution networks and comprehensive regulatory support for importers.

Manufacturer / TM Owner

Zentiva, K.S.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Norifaz (risedronate sodium) is used to manage bone‑remodeling disorders by reducing excessive bone loss.
Osteoporosis in postmenopausal women: reduces bone resorption, leading to increased bone mineral density and a lower risk of vertebral and non‑vertebral fractures.
Osteoporosis in men: enhances bone strength by inhibiting osteoclast activity, thereby improving bone mineral density and decreasing fracture rates.
Paget's disease of bone: suppresses abnormal osteoclastic activity, helping to normalize bone remodeling, reduce bone pain, and improve skeletal architecture.

How It Works

Risedronate sodium binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to the bone surface, the drug is internalized and inhibits the mevalonate pathway, preventing prenylation of small G‑protein signaling molecules. This disruption reduces osteoclast maturation and activity, leading to decreased bone resorption and a net gain in bone mineral density.

Side Effects

Risedronate sodium may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Abdominal pain: mild discomfort in the stomach area.
Nausea: feeling of queasiness often without vomiting.
Dyspepsia: indigestion with bloating or heartburn.
Constipation: difficulty passing stools.
Flatulence: excess gas in the gastrointestinal tract.
Headache: mild to moderate head pain.

Serious or Rare Side Effects

Osteonecrosis of the jaw: exposed bone in the mouth that fails to heal.
Atypical femur fracture: unusual break in the thigh bone with minimal trauma.
Severe esophageal irritation: ulceration or inflammation causing pain on swallowing.
Acute hypocalcemia: markedly low blood calcium levels requiring medical attention.
Severe allergic reaction: rash, swelling, or difficulty breathing.

Precautions & Warnings

Before initiating therapy with Norifaz, several precautionary measures should be considered to ensure safe use.
Assess renal function: avoid use in patients with severe renal impairment (creatinine clearance <30 mL/min).
Ensure adequate calcium and vitamin D intake: supplement as needed to maintain normal serum levels.
Take with a full glass of water: remain upright for at least 30 minutes to reduce esophageal irritation.
Avoid concomitant use of NSAIDs or corticosteroids: these may increase gastrointestinal risk.
Monitor serum calcium: check levels periodically, especially in patients with risk factors for hypocalcemia.
Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Risedronate sodium can interact with other medicines, affecting its absorption or increasing the risk of adverse effects.

Major Interactions (Avoid)

Concurrent use with other bisphosphonates: may amplify bone toxicity.
Co‑administration with calcium, iron, or multivitamin supplements within 2 hours: markedly reduces risedronate absorption.
Use with NSAIDs or corticosteroids: heightened risk of gastrointestinal irritation or ulceration.
Combination with drugs causing hypocalcemia (e.g., loop diuretics): may exacerbate low calcium levels.

Moderate Interactions (Monitor Closely)

Antacids containing aluminum or magnesium: may lower drug bioavailability; separate dosing by at least 30 minutes.
Proton pump inhibitors: altered gastric pH can affect absorption.
Warfarin: potential increase in INR and bleeding risk; monitor coagulation parameters.
Thiazide diuretics: may affect calcium balance; observe serum electrolytes.

Frequently Asked Questions

Norifaz contains risedronate sodium and is prescribed for the treatment of osteoporosis in postmenopausal women and men, as well as for Paget's disease of bone. In each condition the drug works to reduce excessive bone resorption, helping to increase bone density and lower the risk of fractures.

Risedronate sodium binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attach, the drug is taken up and blocks the mevalonate pathway, preventing prenylation of essential signaling proteins. This inhibition reduces osteoclast maturation and activity, leading to decreased bone breakdown and a net gain in bone mineral density.

The dosage of Norifaz is determined by the prescribing clinician based on the patient’s specific condition, renal function, and other clinical factors. Healthcare professionals follow approved prescribing information and adjust the regimen as needed; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for risedronate sodium in pregnancy and lactation are limited, and the drug is generally not recommended for use in these populations. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To request Norifaz, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Norifaz (risedronate) belongs to the bisphosphonate class, similar to alendronate and ibandronate. Compared with some alternatives, risedronate offers a weekly oral dosing schedule and a well‑characterized safety profile. Choice of therapy depends on patient preference, renal function, risk of gastrointestinal side effects, and physician assessment.

Norifaz should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in a bathroom or near a kitchen sink where humidity is high.

Norifaz is taken orally with a full glass of plain water, preferably on an empty stomach. Patients should remain upright for at least 30 minutes after dosing and avoid eating, drinking, or taking other medications during that time to minimize esophageal irritation and ensure optimal absorption.

The most serious adverse events linked to risedronate include osteonecrosis of the jaw, atypical femur fractures, severe esophageal ulceration, acute hypocalcemia, and rare severe allergic reactions. Patients should report persistent jaw pain, unusual thigh pain, difficulty swallowing, or signs of an allergic response to their clinician promptly.

Norifaz is contraindicated in individuals with severe renal impairment (creatinine clearance <30 mL/min), known hypersensitivity to risedronate or other bisphosphonates, and those with active esophageal disorders that delay emptying. It should also be avoided in patients unable to sit or stand upright for at least 30 minutes after dosing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.